• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    IntelGenx and RedHill Biopharma Resubmit RIZAPORT NDA

    Bryan Mc Govern
    Nov. 01, 2017 10:50AM PST
    Pharmaceutical Investing

    IntelGenx announced in partnership with RedHill Biopharma announced they resubmitted the 505(b)(2) NDA to the FDA for RIZAPORT 10 mg.

    IntelGenx (TSXV:IGX; OTCQX:IGXT) announced in partnership with RedHill Biopharma (NASDAQ:RDHL) announced they resubmitted the 505(b)(2) New Drug Application (NDA) to the US Food and Drug Administration (FDA) for RIZAPORT 10 mg.
    As quoted in the press release:

    RIZAPORT is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migraines. RIZAPORT offers an innovative and potentially advantageous therapeutic alternative for many migraine patients, primarily patients who suffer from dysphagia or migraine-related nausea, due to its convenient dosing, facile intake due to the lack of need for water, and neutral flavor.
    Following a first RIZAPORT NDA submission to the FDA in March 2013, IntelGenx and RedHill received a Complete Response Letter (“CRL”) from the Agency. The questions raised by the FDA, which triggered the current resubmission, primarily related to third party chemistry, manufacturing and controls, and the packaging and labeling of the product. The FDA raised no questions or deficiencies relating to RIZAPORT’s safety and bio-equivalence data and did not require additional clinical trials.

    Click here to read the full press release.

    Source: www.marketwired.com

    pharmaceutical investingclinical trialscomplete response letterfood and drug administration
    The Conversation (0)
    Go Deeper
    AI Powered
    Scientist with petri dish.

    Pharma Market Forecast: Top Trends for Pharma in 2025

    Pharma Outlook

    Pharma Outlook

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

     
    IVX:AU

    Cardiol Therapeutics

     
    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×